US20110104819A1 - Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children - Google Patents
Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children Download PDFInfo
- Publication number
- US20110104819A1 US20110104819A1 US12/752,796 US75279610A US2011104819A1 US 20110104819 A1 US20110104819 A1 US 20110104819A1 US 75279610 A US75279610 A US 75279610A US 2011104819 A1 US2011104819 A1 US 2011104819A1
- Authority
- US
- United States
- Prior art keywords
- antigen
- children
- bacteria
- test
- bioassay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Definitions
- the present invention relates to the modification of rapid tests, such as immunochromatographic tests, presently used to diagnose such diseases as otitis media and pneumococcal pneumonia, to reduce the incidence in children particularly of false positive results attributable to nasopharyngeal colonization of otherwise healthy individuals by the same bacteria that are responsible for otitis media and either pneumococcal pneumonia per se or pneumonic diseases clinically indistinguishable therefrom.
- Pneumonic disease and otitis media represent a serious global health problem which is aggravated by the ever-growing ability of bacteria to mutate into forms that are increasingly resistant to the therapeutic effect of the various antibiotics which are the most effective medications against them.
- In the United States alone approximately 4.3 million cases of pneumonia occur in persons of all ages annually and about half of them are caused by bacteria. About 2.5 million visits to physicians are made in the U.S. for the purpose of seeking treatments for otitis media—again about 50% attributable to bacteria.
- Otitis media is known to be largely a disease of young children.
- ICT immunochromatographic
- the present invention involves modifying of the Binax NOW® immunochromatographic (“ICT”) antigen test for use with young children, especially in geographic areas where nasopharyngeal colonization of these children with Streptococcus pneumoniae is a significant clinical manifestation, to markedly diminish or eliminate false positive test results that have been obtained when testing the urine of non-diseased children who are nasopharyngeal carriers of Streptococcus pneumoniae.
- ICT immunochromatographic
- the invention encompasses making analogous modifications of other immunoassay tests for other antigens characteristic of Streptococcus pneumoniae and antigens characteristic of other bacteria that both (1) are causative of pneumonic disease and otitis media in young children and (2) tend to colonize the nasopharynx in uninfected children.
- test modifications rest upon the unexpected discovery that, in general, nasopharyngeal carriage of disease-causing bacteria results in lower concentrations in bodily fluids, including urine, of target bacterial antigens for the ICT tests described in earlier filed, copending patent applications U.S. Ser. No. 09/397,110 and U.S. Pat. No. 518,165, than the concentrations of the same antigens found in bodily fluids of children infected with pneumonic disease or otitis media.
- the modified tests employ reduced concentrations of antibodies to the target bacterial antigens.
- antibodies to the target bacteria are obtained by conventionally injecting a laboratory animal with the bacteria and conventionally obtaining from the animal a blood sample containing antibodies to the injected bacteria after a suitable time interval. Meanwhile, there is obtained from a culture of the same bacteria by a purification process described in the copending applications, an essentially protein-free carbohydrate antigen characteristic of these bacteria. The thus-purified antigen is coupled to a chromatographic column and the antibodies from the animal are rendered antigen-specific by passing them over the antigen coupled to the column.
- the antibodies as so purified and rendered antigen-specific are in part conjugated to a label, such as colloidal gold, and in part placed in an aqueous buffered dilute sucrose solution at a specified antibody concentration level.
- a label such as colloidal gold
- Each ICT bioassay comprises the use of a strip of bibulous material in a housing.
- the strip has a sample receiving zone at one end, a deposit of tagged purified antibody conjugate located immediately ahead of the sample receiving zone, which deposit is rendered flowable by contact with liquid sample, a region through which sample and tagged purified antibodies flow laterally together, a capture zone comprising an immovable bound stripe of purified antibodies deposited thereon from buffered dilute sucrose solution, an upstream control line and by an absorption pad which absorbs the liquid sample and any excess tagged antibodies.
- the capture zone is equipped with a view window in the device which allows the test operator to see color changes developed along the capture line and the control line.
- the test is modified for children to screen out otherwise positive tests of nasopharyngeal carriers of bacteria containing the target antigen by varying the concentration of tagged purified antibody movably deposited on the test strip and the concentration of purified antibody fixedly placed on the strip to form the fixed capture line.
- the objective of the experimental work thereupon performed was to modify the NOW® test in such a way as to reduce markedly or wholly eliminate the positive CARRIER results, thus increasing sensitivity of the test to pneumococcal pneumonia and otitis media disease states caused by Streptococcus pneumoniae while maintaining the specificity of the test at no less than the 90% level and preferably better.
- test strips were prepared as described in earlier filed, copending application Ser. No. 09/399,710 using antibodies to Streptococcus pneumoniae that had been purified and rendered antigen-specific as described in that application.
- the capture lines were striped on the test strip membranes by passing each of them under the delivery tip of a precision pump system at a rate of 0.5 ml. per 6 mm. of membrane.
- the concentration of the capture line was reduced from the 1.25 mg./ml. normally used to each of the concentrations shown in the table.
- the optical density of the gold-purified antibody conjugate which is indicative of concentration, was maintained at 2.0 The test results appear in Table 1:
- test conjugate concentration was reduced approximately 25% from an optical density of 2.0 to an optical density value of 1.5 for all samples run, and the capture line concentrations were as shown in Table II:
- the scrub line was positioned 0.3 milliliters ahead of the capture line in the flow path. Each sample/tagged antibody mixture first flowed over the scrub line and then reached the capture line after “scrubbing”.
- the capture line was maintained at a concentration of 1.0 mg./ml. throughout while the conjugate concentration was held at that producing an optical density of 1.5.
- the number of scrub lines and concentration of each line is each test series in shown in Table IV.
- the scrub lines were separately striped on ahead of the capture line in the flow path, with the first one being 2 mm ahead, the second one 4 mm ahead and the third one, 6 mm. ahead.
- the 2 or 3 scrub lines employed in that series had identical antibody concentrations.
- test series on urines from other populations of children including nasopharyngeal carriers are planned with variations in other test parameters.
Abstract
Description
- The present invention relates to the modification of rapid tests, such as immunochromatographic tests, presently used to diagnose such diseases as otitis media and pneumococcal pneumonia, to reduce the incidence in children particularly of false positive results attributable to nasopharyngeal colonization of otherwise healthy individuals by the same bacteria that are responsible for otitis media and either pneumococcal pneumonia per se or pneumonic diseases clinically indistinguishable therefrom.
- Pneumonic disease and otitis media, especially in children up to the age of about 12 years, represent a serious global health problem which is aggravated by the ever-growing ability of bacteria to mutate into forms that are increasingly resistant to the therapeutic effect of the various antibiotics which are the most effective medications against them. In the United States alone, approximately 4.3 million cases of pneumonia occur in persons of all ages annually and about half of them are caused by bacteria. About 2.5 million visits to physicians are made in the U.S. for the purpose of seeking treatments for otitis media—again about 50% attributable to bacteria. Otitis media is known to be largely a disease of young children.
- It has been estimated that about 4 million children throughout the world die annually from acute respiratory diseases, preponderantly in developing countries. Studies show that Streptococcus pneumoniae is the leading cause of bacterial pneumonia in developing countries and a major cause of child mortality.
- All of these problems have been complicated by the fact that accurate diagnosis of bacterially caused respiratory infection, and acute ear infection (i.e., otitis media) in children was slow and difficult until recently. It has been known for some years that bacterial antigens were present in bodily fluids of persons infected with pneumococcal pneumonia, such as e.g., blood, sputum, urine, etc., but until recently there was little progress in using this knowledge as the basis for developing a reliable test for such antigens. In the meantime, the standard for accurate diagnosis of pneumococcal pneumonia and other Streptococcus pneumoniae—caused diseases has been a bacterial culture test which usually required some days to complete and had other considerable drawbacks, such e.g., as the difficulty of obtaining a suitable sample for culturing and the drawback of having to medicate the patient while awaiting the culture test outcome with a broad spectrum antibiotic, all of which drawbacks are well documented in the medical literature.
- In 1999, the United States Food and Drug Administration approved a rapid (i.e. about 20 minutes) immunochromatographic (“ICT”) bioassay for the detection of Streptococcus pneumoniae in bodily fluids, particularly urine. This test, which is commercially available from Applicants' assignee under the trademark NOW®, detects the C-polysaccharide antigen which is present in all serotypes of Streptococcus pneumoniae. In adults and most teenagers, the test has a sensitivity of 78% for pneumococcal pneumonia infections and 82-86% for bacteremic forms thereof and a specificity of over 95%. See Dominguez, J., Gali, N. Blanco, S. et al, Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine, Chest 2001, vol. 119, 243-9; Yu V. L., Kellog, J. A, Plouffe, J. F. et al, Evaluation of the Binax Urinary, Gram stain and sputum culture for Streptococcus pneumoniae in patients with community-acquired pneumonia, 38th Annual Meeting of the Infectious Disease Society of America, New Orleans, La., Abstract #262 (2001).
- The NOW® bioassay is described and claimed in co-pending, commonly assigned U.S. patent application Ser. No. 09/399,710 filed Sep. 16, 1999 and its parent application Ser. No. 09/156,486 filed Sep. 18, 1998 and now abandoned.
- A study of pneumonia conducted in China found that children with nasopharyngeal carriage of Streptococcus pneumoniae had high rates of positive urine results in the NOW® test even when they had no pneumonic disease and that the test results accordingly did not fit the sensitivity and specificity profile established with adult subjects. A study in Gambia found that 87% of well children tested were nasopharyngeal carriers of Streptococcus pneumoniae and that 55% of these, or about 47% of this population, gave false positive results in the Binax NOW® test. See Adegbola, R. A., Obaro, S. K., Biney, E. and Greenwood, B. M., Evaluation of Binax NOW® Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus, Pediatr. Infect. Dis. J. 2001, July; 20 (7) 718-719. See also Dowell, S. F., Garman, R. L., Liu, G., Levine, O. S. and Yang, Y. H., Evaluation of Binax NOW as assay for the detection of pneumococcal antigen in urine samples performed among pediatric patients, Clin Infect Dis. J. 2001, vol. 32, 824-825 (2001). A similar study conducted among 210 children in Quito, Ecuador, confirmed that urine from children with nasopharyngeal carriage of Streptococcus pneumoniae gives a high proportion of false positive results in the Binax NOW® test. See Hamer, D., Egas, J., Estrella, B., MacLood, W. et al, 2002, An assessment of the Binax NOW Streptococcus Pneumoniae urinary test in children with Nasopharyngeal pneumococcal colonization, (Publication in press)
- An article reviewing published studies performed on Scandinavian and Israeli children confirms that young children in these areas have a high rate of nasopharyngeal colonization, not only of Streptococcus pnuemoniae but also of the bacteria that are known to cause disease states that resemble pneumococcal pneumonia, including especially non-typable Haemophilus influenzae and Moraxella catarrhalis which, with Strepococcus pneumoniae, are the most common causes of otitis media. Among other agents that tend to colonize the nasopharynx and are causatives of both pneumonic illness clinically very similar to pneumococcal pneumonia and otitis media are Staphylococcus aureus, a number of other bacteria and some viruses. See Harper, M. B., Nasopharyngeal colonization with pathogens causing otitis media; how does this information help us? Pediatr Infec. Dis. J. vol. 18, 1120-1124 (1999)
- Copending, commonly assigned U.S. application Ser. No. 09/518,165 filed Mar. 1, 2002, describes and claims rapid immunochromatographic tests for detecting bacterial carbohydrate antigens in human bodily fluids, including urine.
- The methodology for lessening and/or eliminating false positives in child carriers who are colonized nasopharyngeally as described herein is applicable to the modification of tests for antigens of other bacteria which tests are disclosed in copending, commonly assigned application Ser. No. 09/518,165 as well as to the test for Streptococcus pneumoniae antigens described in copending commonly assigned application Ser. No. 09/399,710.
- In general, the development of rapid, reliable, specific and sensitive assays for antigens of bacteria causative of common respiratory tract and ear infections in children—and especially pneumonia and otitis media because of their high incidence—is important to complement the strategies that the Centers for Disease Control in the United States and the World Health Organization globally have formulated for decelerating the pace of development by causative bacteria of strains resistant to antibiotic therapy.
- The present invention involves modifying of the Binax NOW® immunochromatographic (“ICT”) antigen test for use with young children, especially in geographic areas where nasopharyngeal colonization of these children with Streptococcus pneumoniae is a significant clinical manifestation, to markedly diminish or eliminate false positive test results that have been obtained when testing the urine of non-diseased children who are nasopharyngeal carriers of Streptococcus pneumoniae. The invention encompasses making analogous modifications of other immunoassay tests for other antigens characteristic of Streptococcus pneumoniae and antigens characteristic of other bacteria that both (1) are causative of pneumonic disease and otitis media in young children and (2) tend to colonize the nasopharynx in uninfected children.
- The test modifications rest upon the unexpected discovery that, in general, nasopharyngeal carriage of disease-causing bacteria results in lower concentrations in bodily fluids, including urine, of target bacterial antigens for the ICT tests described in earlier filed, copending patent applications U.S. Ser. No. 09/397,110 and U.S. Pat. No. 518,165, than the concentrations of the same antigens found in bodily fluids of children infected with pneumonic disease or otitis media.
- The modified tests employ reduced concentrations of antibodies to the target bacterial antigens.
- The objective of the modifications, which is to maintain high specificity for diseased patient samples and to improve sensitivity to those samples by screening out samples from healthy, but nasopharyngeally colonized, children which gave false positives in the standard NOW® test for Streptococcus pneumoniae.
- The NOW® bioassay for identifying the characteristic C-polysaccharide antigen of Streptococcus pneumoniae present in all serotypes of these bacteria, has been demonstrated to be highly satisfactory in enabling physicians to make rapid, accurate diagnoses of a variety of Streptococcus pneumoniae—caused disease states in adults by coordinating carefully observed clinical symptoms with the test results. This ICT test is described and claimed in commonly assigned, copending U.S. patent application Ser. No. 09/399,710. U.S. application Ser. No. 09/518,165, also copending and commonly assigned, discloses how to construct and perform analogous ICT bioassays which target characteristic carbohydrate antigens of other bacteria, including but by no means limited to non-typable Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus.
- The modifications disclosed herein of the NOW® test disclosed and claimed in U.S. Ser. No. 09/399,710 render the test as so modified highly useful in enabling physicians to make rapid, accurate diagnoses of pneumococcal pneumonia and/or otitis media caused by Streptococcus pneumoniae in children, which diagnoses are based on the modified test results combined with clinical observations of the individual patients. Analogous modifications of the tests covered in U.S. Ser. No. 09/518,165 render those tests as so modified very useful in enabling physicians to make rapid, accurate diagnoses of pneumonic diseases and otitis media of other bacterial origin in children, by combining the modified test results with clinical observation of individual child patients. Similar modifications may be made to any bioassay for an antigen characteristic of bacteria that tend to colonize nasopharyngeally in children and are causatives of pneumonic disease and/or otitis media, in order to improve diagnostic reliability on the assay results by diminishing or eliminating false positive results in children due to nasopharyngeal colonization.
- To put the specific modified tests described in the examples of this application in perspective, a brief summary of the bioassay format described in both of the prior copending applications is provided. Succinctly, antibodies to the target bacteria are obtained by conventionally injecting a laboratory animal with the bacteria and conventionally obtaining from the animal a blood sample containing antibodies to the injected bacteria after a suitable time interval. Meanwhile, there is obtained from a culture of the same bacteria by a purification process described in the copending applications, an essentially protein-free carbohydrate antigen characteristic of these bacteria. The thus-purified antigen is coupled to a chromatographic column and the antibodies from the animal are rendered antigen-specific by passing them over the antigen coupled to the column. The antibodies as so purified and rendered antigen-specific are in part conjugated to a label, such as colloidal gold, and in part placed in an aqueous buffered dilute sucrose solution at a specified antibody concentration level. Each ICT bioassay comprises the use of a strip of bibulous material in a housing. The strip has a sample receiving zone at one end, a deposit of tagged purified antibody conjugate located immediately ahead of the sample receiving zone, which deposit is rendered flowable by contact with liquid sample, a region through which sample and tagged purified antibodies flow laterally together, a capture zone comprising an immovable bound stripe of purified antibodies deposited thereon from buffered dilute sucrose solution, an upstream control line and by an absorption pad which absorbs the liquid sample and any excess tagged antibodies. The capture zone is equipped with a view window in the device which allows the test operator to see color changes developed along the capture line and the control line. When the test is run and the target bacterial antigen is present in the liquid sample, after the sample is applied to the strip and picks up the tagged antibodies as it flows along, conjugates of tagged antibody and target antigen form during further flow to the capture line, where tagged antibody-target antigen-fixed antibody “sandwiches” form and become visible as a result of the massing of tag along the fixed capture line.
- According to the present invention, the test is modified for children to screen out otherwise positive tests of nasopharyngeal carriers of bacteria containing the target antigen by varying the concentration of tagged purified antibody movably deposited on the test strip and the concentration of purified antibody fixedly placed on the strip to form the fixed capture line.
- It is noted that the nasopharyngeal colonization of children is said in the literature to decrease with increasing age of the children. By about age 12 and in many cases earlier, the problem has disappeared and the problem of false positives has likewise essentially disappeared.
- In approaching the problem of false positives obtained in using the NOW® test on samples from nasopharyngeally colonized child carriers of Streptococcus pneumoniae, 210 individual samples of urine were obtained from the Ecuadorian study described by the Hamer et al article cited above. These samples were preliminarily divided into three groups based on information that accompanied them as received,
- 1. Samples that had tested negative in a bacterial culture test and also in the NOW® test, all of which were labeled NEGATIVE.
- 2. Samples that had tested positive in the same bacterial culture test and also in the NOW® test, all of which were labeled POSITIVE.
- 3. Samples which had tested negative in the same culture test but had tested positive in the NOW® test, which were labeled CARRIER.
- The objective of the experimental work thereupon performed was to modify the NOW® test in such a way as to reduce markedly or wholly eliminate the positive CARRIER results, thus increasing sensitivity of the test to pneumococcal pneumonia and otitis media disease states caused by Streptococcus pneumoniae while maintaining the specificity of the test at no less than the 90% level and preferably better.
- Randomly selected samples from the groups 2 and 3 of the Ecuadorian childrens' urine samples described above were used to conduct the tests described in the following examples.
- In all of these examples, test strips were prepared as described in earlier filed, copending application Ser. No. 09/399,710 using antibodies to Streptococcus pneumoniae that had been purified and rendered antigen-specific as described in that application. In all of these tests, the capture lines were striped on the test strip membranes by passing each of them under the delivery tip of a precision pump system at a rate of 0.5 ml. per 6 mm. of membrane.
- In this example, the concentration of the capture line was reduced from the 1.25 mg./ml. normally used to each of the concentrations shown in the table. The optical density of the gold-purified antibody conjugate which is indicative of concentration, was maintained at 2.0 The test results appear in Table 1:
-
TABLE I Samples Antibody Concentration Carriers Giving POSITIVES of Capture Line Negative Result % Positive 0.3 mg./ml. 1 of 7 = 14% 100% samples 0.5 mg./ml. 4 of 11 = 36% 100% samples 1.0 mg./ml. 1 of 11 = 9% 100% samples - These results show that reducing capture line concentration alone to 0.3 mg./ml. had no significant effect on elimination of false positive results in the carrier samples. It was decided to run further tests with varying capture line antibody concentrations below 0.5 mg./ml.
- In this Example, the test conjugate concentration was reduced approximately 25% from an optical density of 2.0 to an optical density value of 1.5 for all samples run, and the capture line concentrations were as shown in Table II:
-
TABLE II Antibody Concentration Carriers Giving POSITIVES of Capture Line Negative Result % Positive 0.1 mg./ml. 1 of 6 = 17% 66% samples 0.2 mg./ml. 9 of 13 = 69% 100% samples 0.3 mg./ml. 10 of 14 = 72% 100% samples 0.4 mg./ml. 7 of 14% = 50% 100% samples - These results show that the specificity of the test declined when a capture line concentration as low as 0.1 mg./ml. was employed. However, with the reduced optical density (i.e. conjugate concentration) in all tests, it was calculated that sensitivity of the test to disease states due to elimination of false positives increased to more than 90% with a capture line concentration of 0.3 mg./ml., while the tests at these capture line and conjugate concentrations made on Positive samples were all positive, indicating specificity of the test was unaffected. Raising the capture line concentrations to 0.4 mg./ml. decreased sensitivity by raising the proportion of false positives. It was also noted that the 0.1 mg./ml. capture line concentration reduced the ability of the test to detect Positive samples from diseased children and had little effect on reducing false positives.
- Using conjugate of optical density 1.5 and a capture line concentration of 1.0 mg./ml. in all tests, the addition of a “scrub” line of varying concentration was tested on a number of samples, as shown in Table III. The scrub line was experimented with to see if by “scrubbing” out a portion of the antigen present in both the carrier samples and the Positive samples, which generally have significantly higher antigen levels than the carrier samples, the sensitivity of the test toward disease detection could be increased without any major effect on test specificity.
- For the test strips used in these tests, the scrub line was positioned 0.3 milliliters ahead of the capture line in the flow path. Each sample/tagged antibody mixture first flowed over the scrub line and then reached the capture line after “scrubbing”.
-
TABLE III Scrub Line Carriers Giving Antibody Concentration Negative Result POSITIVES 0.3 mg./ml. 22 of 35 = 63% 7 of 8 = 87.5% samples samples 0.4 mg./ml. 19 of 35 = 54% 5 fof 6 = 83% samples samples 0.5 mg./ml. 18 of 29 = 62% 5 of 8 = 62.5% samples samples 0.6 mg./ml. 21 of 29 = 72% 4 of 8 = 50% samples samples - While these tests generally showed increasing elimination of false positives with increasing concentration of the scrub line, the specificity of the test was adversely affected. Moreover, increasing the concentration of the scrub line did not remove all antigen from of the false positive samples and it was therefore decided to try multiple scrub lines, each of lower concentration than the 0.3 mg./ml. scrub line used in one series of tests in this Example.
- In this series of test runs, the capture line was maintained at a concentration of 1.0 mg./ml. throughout while the conjugate concentration was held at that producing an optical density of 1.5. The number of scrub lines and concentration of each line is each test series in shown in Table IV. The scrub lines were separately striped on ahead of the capture line in the flow path, with the first one being 2 mm ahead, the second one 4 mm ahead and the third one, 6 mm. ahead. In each test series, the 2 or 3 scrub lines employed in that series had identical antibody concentrations.
-
TABLE IV Antibody No.# of Concentration Carriers Testing Positive Scrub Lines of Each Scrub Line Negative (% Positive) 2 0.1 mg./ml. 4 of 11 = 36% 10 of 11 = 91% samples samples 2 0.15 mg./ml. 5 of 9 = 55% 3 of 5 = 60% samples samples 2 0.2 mg./ml. 5 of 10 = 50% 3 of 5 = 60% samples samples 2 0.25 mg./ml. 7 of 11 = 82% 7 of 11 = 70% samples samples 3 0.1 mg./ml. 10 of 10 = 100% 1 of 5 = 20% samples samples - While the test series using 3 scrub lines of 0.1 mg./ml. antibody concentration was effective in wholly eliminating false positives it also eliminated 80% of the Positive samples. Putting aside the 3-scrub line test series, the results in the table reflect that the amount of antigen removed from the Positive samples in those series with 2 scrub lines, each having an antibody concentration above 0.1 mg./ml. adversely affected the test results on Positive samples, decreasing specificity and sensitivity.
- It is intended to run further tests using two and three scrub lines at lower concentrations than were incorporated in this series, to try to eliminate false positives without adversely affecting the sensitivity and specificity of the test toward diseased patient's samples. It is also intended to try combinations of 1-3 scrub lines with the capture line concentration and the optical density maintained at the level currently used for the NOW® test on the premise that scrubbing out the level of antigen in the sample in the urine of most carriers prior to the capture line in both carrier and positive samples may leave a sufficient antigen level in the urines of diseased patients to be detected at capture line of higher antibody concentration. In this regard, it is important to recognize that the lack of any statistically significant figures showing the level of antigen in the urine of humans infected with Streptococcus pneumoniae versus the level of antigen in urine of healthy children nasopharyngeally colonized with Streptococcus pneumoniae makes it necessary to proceed empirically in establishing how to screen healthy carriers of bacteria known to be causative of otitis media and pneumococcal diseases from actually diseased children. The medically recognized dangers in medicating otherwise healthy carrier children with antibiotics based on false positive test results render it urgent that this work, empirical though it be, continue forward rapidly.
- Further test series on urines from other populations of children including nasopharyngeal carriers are planned with variations in other test parameters.
- From the tests to date, the ultimate objective of maintaining test specificity at 90% or better and increasing sensitivity of the test to diseased children while eliminating or at least minimizing false positives due to nasopharyngeal colonization (i.e. carriers) is clearly achievable by several routes, all involving reduced conjugate concentration and reduced capture line antibody concentration in comparison to the concentrations employed in the NOW® test for adults. Some of them, involving the introduction of at least one scrub line positioned prior to the capture line in the sample flow path of the test devices are believed to be capable of being combined with the present concentrations of antibodies on the capture line and in the conjugate that are used in the NOW® test. Inasmuch as those skilled in the art of immunology will readily conceive of permutations and combinations of variables that will be successful, it is intended that the invention as disclosed be limited only insofar as the appended claims may require.
- It is also clear that other immunoassays for antigens characteristic of bacteria that colonize the nasopharynx area of children and are causative of pneumococcal and ear infections in children may be modified for use in children so as to increase the diagnostic reliability of the assay by reducing substantially, or eliminating, false positive results by either reducing the overall concentration of antibodies used in the specific assay or combining concentration levels in use in tests designed for the adult population with one or more “scrub” lines. In either case modifications will be arrived at by applying study techniques analogous to those used herein to arrive at specific limits—and for that reason also, this invention is limited only by the appended claims.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/752,796 US20110104819A1 (en) | 2002-02-27 | 2010-04-01 | Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/083,476 US7718375B2 (en) | 2002-02-27 | 2002-02-27 | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
US12/752,796 US20110104819A1 (en) | 2002-02-27 | 2010-04-01 | Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,476 Continuation US7718375B2 (en) | 2002-02-27 | 2002-02-27 | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110104819A1 true US20110104819A1 (en) | 2011-05-05 |
Family
ID=27765304
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,476 Expired - Fee Related US7718375B2 (en) | 2002-02-27 | 2002-02-27 | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
US12/752,796 Abandoned US20110104819A1 (en) | 2002-02-27 | 2010-04-01 | Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,476 Expired - Fee Related US7718375B2 (en) | 2002-02-27 | 2002-02-27 | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
Country Status (3)
Country | Link |
---|---|
US (2) | US7718375B2 (en) |
AU (1) | AU2003217730A1 (en) |
WO (1) | WO2003072806A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824997B1 (en) | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
US9134303B1 (en) | 1998-08-25 | 2015-09-15 | Alere Scarborough, Inc. | ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto |
US7718375B2 (en) * | 2002-02-27 | 2010-05-18 | Binax, Inc. | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
KR101064594B1 (en) * | 2008-07-30 | 2011-09-15 | 전남대학교산학협력단 | Rfid system for analyzing carrying route and unloading spot of object |
CN102264404A (en) | 2008-12-23 | 2011-11-30 | 美国政府卫生和公众服务部疾病预防和控制中心 | Lung aerosol collection device |
CN102135540A (en) * | 2010-09-03 | 2011-07-27 | 李克生 | Detection method of staphylococcus aureus and gold-labeled rapid diagnosis kit for same and preparation method thereof |
EP2696193A1 (en) | 2012-08-06 | 2014-02-12 | Andrew Wheeler | Assay detection systems and methods |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
TWI521063B (en) | 2015-03-10 | 2016-02-11 | 國立交通大學 | Biological sensing device and method for separating biomolecule |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806312A (en) * | 1985-08-28 | 1989-02-21 | Miles Inc. | Multizone analytical element having detectable signal concentrating zone |
US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
US7718375B2 (en) * | 2002-02-27 | 2010-05-18 | Binax, Inc. | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005978A1 (en) | 1987-12-14 | 1989-06-29 | Liotta Lance A | Layered immunoassay device containing fluid flow barrier |
-
2002
- 2002-02-27 US US10/083,476 patent/US7718375B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 AU AU2003217730A patent/AU2003217730A1/en not_active Abandoned
- 2003-02-27 WO PCT/US2003/005786 patent/WO2003072806A2/en not_active Application Discontinuation
-
2010
- 2010-04-01 US US12/752,796 patent/US20110104819A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806312A (en) * | 1985-08-28 | 1989-02-21 | Miles Inc. | Multizone analytical element having detectable signal concentrating zone |
US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
US7718375B2 (en) * | 2002-02-27 | 2010-05-18 | Binax, Inc. | Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children |
Also Published As
Publication number | Publication date |
---|---|
AU2003217730A1 (en) | 2003-09-09 |
WO2003072806A2 (en) | 2003-09-04 |
US20050260694A1 (en) | 2005-11-24 |
WO2003072806A3 (en) | 2004-03-25 |
US7718375B2 (en) | 2010-05-18 |
AU2003217730A8 (en) | 2003-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110104819A1 (en) | Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children | |
Obaro et al. | The pneumococcus: carriage, disease and conjugate vaccines | |
Mani | Acute pneumonia and its complications | |
Markowitz et al. | Tick-borne tularemia: an outbreak of lymphadenopathy in children | |
Beck-Sague et al. | Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study | |
Pothoulakis et al. | Clostridium difficile colitis and diarrhea | |
Stull et al. | Epidemiology and natural history of urinary tract infections in children | |
Woolfson et al. | Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. | |
Giebink et al. | Otitis media: the spectrum of middle ear inflammation | |
Bisno et al. | Factors influencing serum antibody responses in streptococcal pyoderma | |
Broughton et al. | Role of adherence in the pathogenesis of neonatal group B streptococcal infection | |
Kohli et al. | Value of serum C-reactive protein concentrations in febrile children without apparent focus | |
Donaldson et al. | Characteristics of aerobic gram-negative bacteria colonizing critically III patients. | |
Israele et al. | The role of bacterial virulence factors and Tamm-Horsfall protein in the pathogenesis of Escherichia coli urinary tract infection in infants | |
Augenbraun et al. | Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture | |
Yang et al. | Nasopharyngeal colonization with nontypeable Haemophilus influenzae in chinchillas | |
Marshak et al. | Recurrent pneumococcal otitis media in the chinchilla: a longitudinal study | |
Dhar et al. | Unusual non-serogroup O1 Vibrio cholerae bacteremia associated with liver disease | |
Bjuggren et al. | Occult sinusitis in children | |
Saluja et al. | Scrub typhus: Epidemiology, clinical presentation, diagnostic approach, and outcomes | |
Turner et al. | Counterimmunoelectrophoresis of urine for diagnosis of bacterial pneumonia in pediatric outpatients | |
Sturm et al. | Pediatric Legionnaires' disease: diagnosis by direct immunofluorescent staining of sputum | |
JP3635303B2 (en) | Prevention of sudden infant death | |
Chiarucci et al. | Absence of antibiotic-resistant Streptococcus pneumoniae pharyngeal colonization in Cleveland children with sickle cell disease | |
Giacoia et al. | Respiratory infections in infants on mechanical ventilation: the immune response as a diagnostic aid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND Free format text: SECURITY AGREEMENT;ASSIGNORS:ADVANTAGE DIAGNOSTICS CORPORATION;ALERE MEDICAL INCORPORATED;ALERE SAN DIEGO, INC.;AND OTHERS;REEL/FRAME:026557/0287 Effective date: 20110630 |
|
AS | Assignment |
Owner name: BINAX, INC., MAINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIASIO, ROGER N.;WAREING, MADELINE;SIGNING DATES FROM 20020408 TO 20020409;REEL/FRAME:026838/0304 Owner name: ALERE SCARBOROUGH, INC., MAINE Free format text: CHANGE OF NAME;ASSIGNOR:BINAX, INC.;REEL/FRAME:026838/0452 Effective date: 20100701 |
|
AS | Assignment |
Owner name: BINAX, INC., MAINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIASIO, ROGER N.;WAREING, MADELINE;SIGNING DATES FROM 20020408 TO 20020409;REEL/FRAME:030522/0981 Owner name: ALERE SCARBOROUGH, INC., MAINE Free format text: CHANGE OF NAME;ASSIGNOR:BINAX, INC.;REEL/FRAME:030523/0075 Effective date: 20100701 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INVERNESS MEDICAL - BIOSTAR INC., MASSACHUSETTS Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ISCHEMIA TECHNOLOGIES, INC., MASSACHUSETTS Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: MATRITECH, INC., MASSACHUSETTS Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ALERE SCARBOROUGH, INC., MAINE Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ALERE MEDICAL, INC., NEVADA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: HEMOSENSE, INC., CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ALERE SAN DIEGO, INC., CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: APPLIED BIOTECH, INC., CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: INSTANT TECHNOLOGIES, INC., VIRGINIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: BIOSITE INCORPORATED, CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: CHOLESTECH CORPORATION, CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: AMEDITECH INC., CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: GENECARE MEDICAL GENETICS CENTER, INC., NORTH CARO Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ADVANTAGE DIAGNOSTICS CORPORATION, CALIFORNIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: MATRIA HEALTHCARE, INC., GEORGIA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: ZYCARE, INC., NORTH CAROLINA Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 Owner name: BINAX, INC., MAINE Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581 Effective date: 20150618 |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT, MARYLAND Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:ALERE CONNECT, LLC;ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.);ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.);AND OTHERS;REEL/FRAME:036994/0192 Effective date: 20150618 Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERA Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:ALERE CONNECT, LLC;ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.);ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.);AND OTHERS;REEL/FRAME:036994/0192 Effective date: 20150618 |
|
AS | Assignment |
Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT, MARYLAND Free format text: ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT;REEL/FRAME:037115/0498 Effective date: 20151113 Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR Free format text: ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT;REEL/FRAME:037115/0498 Effective date: 20151113 |
|
AS | Assignment |
Owner name: ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.), MAINE Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.), CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.), CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.), FLORIDA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.), CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: ESCREEN, INC., KANSAS Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: STANDING STONE, LLC, CONNECTICUT Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.), F Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHO Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: ALERE CONNECT, LLC, ARIZONA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA A Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 Owner name: IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258 Effective date: 20171003 |